Accessible Immunotherapies and Business Excellence Through Innovative Science

Tevogen Bio® is a leading NextGen clinical-stage Specialty Immunotherapy Biotech developing off-the-shelf Precision T cell therapeutics in virology, oncology, and neurology. Tevogen's leadership team, with decades of drug development and global commercialization experience in several therapeutic areas, believes that affordable personalized immunotherapies are the next frontier of medicine, and that advanced science and disruptive business models are necessary to sustain and accelerate medical innovation. The company has developed core organizational capabilities, successfully completed the proof-of-concept (POC) clinical trial of its lead product candidate, TVGN 489, in which no dose limiting toxicities or treatment-related adverse events were observed, established a robust research pipeline, and earned considerable brand recognition including Nobel Peace Prize nomination for its patient centric, purpose driven business model, all in less than two years since its formation.

Portfolio & IP: Research pipeline includes off-the-shelf, allogeneic genetically unmodified precision CD8+ T Lymphocyte therapeutics for the treatment of serious viral infections, viral-induced cancers, several non-virally induced common cancers, and neurologic diseases (multiple sclerosis). The intellectual property portfolio includes three granted U.S. patents, eight pending patents and is owned solely by the company.

Current Pipeline and Research Portfolio



Leadership: A team of senior industry leaders and preeminent scientists with extensive track records of drug development and global commercialization in almost all therapeutic areas. Tevogen has established its Corporate & Commercial Hub in Warren, New Jersey and its R&D Center and Preclinical Research Facility in Philadelphia within two years of formation of the company.

Sustainable Business Model: Cell and Gene therapies are expected to be the norm, not the exception. However, patient access barriers remain a risk factor for the sustainability of the cell and gene therapy sector.

Tevogen's inventions are designed to overcome both cost and geography related patient access barriers and transform cancer treatment by developing cell therapies as first-line options. The company aspires and is designed to be the very first biotech to achieve commercial success and patient affordability through advanced science and efficient business models.

Major Achievements and Future Milestones



The Clinical Experience with Tevogen's Precision T Cell Technology: Tevogen's lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients who are unable to take or unlikely to benefit from currently available preventative or therapeutic options, as well as a subset of patients suffering from long COVID.

TVGN 489 POC Trial Experience has Validated the Utility and Compelling Potential of Tevogen's Precision T Cell Technology and Cost-Efficient Cell Therapy Manufacturing Capability

- No dose limiting toxicities or treatment-related adverse events, including Cytokine Release Syndrome
- Correction of lymphopenia, reduction of inflammatory markers and viral load
- Trial patients were infected by Delta and a wide range of Omicron variants

Tevogen is working towards maximizing the value of its technology platforms and business model to develop and manufacture accessible immunotherapies in virology, oncology, and neurology.

Please contact Tevogen Investor Relations for Corporate Overview: ir@tevogen.com

Forward-Looking Statements

This document contains certain forward-looking statements, including statements relating to Tevogen Bio®'s development of, the potential benefits of and patient access to its innovations in virology, oncology and neurology. Forward-looking statements may be able to be identified by words such as may, could, expect, possible, potential, goal, opportunity, and similar words or their opposites. These statements are based on management's current expectations, assumptions, estimates, projections, and beliefs and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

In any forward-looking statement in which Tevogen Bio® Inc expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but due to various factors, there can be no assurance that the statement or expectation or belief will be achieved. These factors include, among others, risks related to the conduct and results of current or pending clinical trials, intellectual property protection, financial projections, and actions by the FDA/EMA.

Tevogen Bio® does not undertake an obligation to update the forward-looking statements, except as required by applicable laws.